Soleno Therapeutics, Inc. vs Dynavax Technologies Corporation: SG&A Expense Trends

Biotech SG&A Expenses: Dynavax vs. Soleno (2014-2023)

__timestamp	Dynavax Technologies Corporation	Soleno Therapeutics, Inc.
Wednesday, January 1, 2014	17763000	2917513
Thursday, January 1, 2015	22180000	7878291
Friday, January 1, 2016	37257000	8366794
Sunday, January 1, 2017	27367000	6610381
Monday, January 1, 2018	64770000	6556000
Tuesday, January 1, 2019	74986000	6930000
Wednesday, January 1, 2020	79256000	8758000
Friday, January 1, 2021	100156000	10806000
Saturday, January 1, 2022	131408000	9844000
Sunday, January 1, 2023	152946000	13481000

Unveiling the hidden dimensions of data

SG&A Expense Trends: Soleno Therapeutics vs. Dynavax Technologies

In the ever-evolving landscape of biotechnology, understanding financial trends is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Soleno Therapeutics, Inc. and Dynavax Technologies Corporation from 2014 to 2023. Over this period, Dynavax's SG&A expenses surged by an impressive 760%, reflecting its aggressive growth strategy. In contrast, Soleno's expenses increased by approximately 360%, indicating a more conservative approach.

Key Insights

Dynavax Technologies: Starting at 17.8 million in 2014, their SG&A expenses reached 152.9 million by 2023, highlighting a robust expansion.
Soleno Therapeutics: From a modest 2.9 million in 2014, their expenses grew to 13.5 million in 2023, showcasing steady growth.

These trends underscore the strategic financial decisions each company has made, offering valuable insights for investors and industry analysts alike.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025

Similar Statistics

Breaking Down SG&A Expenses: Novo Nordisk A/S vs Soleno Therapeutics, Inc.

Selling, General, and Administrative Costs: AbbVie Inc. vs Soleno Therapeutics, Inc.

Operational Costs Compared: SG&A Analysis of Amgen Inc. and Soleno Therapeutics, Inc.

Selling, General, and Administrative Costs: Regeneron Pharmaceuticals, Inc. vs Soleno Therapeutics, Inc.

Operational Costs Compared: SG&A Analysis of Catalent, Inc. and Soleno Therapeutics, Inc.

Cost Management Insights: SG&A Expenses for Blueprint Medicines Corporation and Dynavax Technologies Corporation

Madrigal Pharmaceuticals, Inc. and Dynavax Technologies Corporation: SG&A Spending Patterns Compared

Apellis Pharmaceuticals, Inc. or Soleno Therapeutics, Inc.: Who Manages SG&A Costs Better?

Comparing SG&A Expenses: ACADIA Pharmaceuticals Inc. vs Soleno Therapeutics, Inc. Trends and Insights

Bausch Health Companies Inc. or Soleno Therapeutics, Inc.: Who Manages SG&A Costs Better?

Amicus Therapeutics, Inc. and Soleno Therapeutics, Inc.: SG&A Spending Patterns Compared

Selling, General, and Administrative Costs: Vericel Corporation vs Dynavax Technologies Corporation